Bayer Presses Its Case on Multiple Fronts as a $2.45bn Pipeline Bet and a J&J Lawsuit Tell a Broader Story

Bayer hits monthly high as Supreme Court glyphosate pre-emption decision, EU GMO labelling changes, and a reinvigorated legal offensive against J&J drive investor optimism.

Bayer’s stock shot to a monthly high on Thursday, climbing 4.6% to €37.51, as a constellation of legal and regulatory signals converged to lift the mood around the beleaguered pharmaceuticals-to-agrochemicals group. The gain — the strongest in the DAX — snapped a period of technical drift that had left the shares hovering between their 50-day and 200-day moving averages, and pushed the stock back into positive territory for 2026.

What made the move noteworthy was its breadth. Three distinct triggers aligned: the imminent United States Supreme Court ruling on glyphosate pre-emption, a long-awaited European Union policy shift on genetically modified food labelling, and a reinvigorated legal offensive against Johnson & Johnson over claims of misleading superiority in prostate cancer. Each, in its own way, signals that Bayer is no longer content to simply wait for clarity.

The high court’s decision in the “Durnell” case — expected before the end of June — remains the binary event that could transform Bayer’s legal landscape. A victory would allow the company to argue that federal approval of glyphosate by the EPA pre-empts state-law claims, potentially neutering the vast majority of the roughly 65,000 pending Roundup lawsuits. Yet the oral arguments left observers deeply uncertain. Stanford law professor Nora Freeman Engstrom cautioned that even a win on pre-emption would not extinguish all claims: plaintiffs could still pursue negligence, design defect or fraud theories. The ruling, she argued, would “narrow, not end” the litigation. That nuance has done little to dampen the binary trade mentality surrounding the stock. UBS analyst Matthew Weston, who holds a €52 price target — nearly 40% above the current level — made clear that the today’s surge remains a high-stakes hope trade.

Alongside the courtroom drama, Bayer has been quietly strengthening its hand in the operating business. The company’s decision to take on Johnson & Johnson in court over Nubeqa is a revealing piece of aggression. On June 15, Bayer amended a lawsuit accusing J&J of making false superiority claims for its rival prostate cancer drug, misusing real-world evidence, and misleading doctors and patients. Bayer is seeking a permanent injunction and damages — a move that underscores how fiercely it will defend a drug that is already delivering significant sales momentum, buoyed by new indications.

Equally telling is the recent acquisition of Perfuse Therapeutics, an American biopharma company focused on ophthalmology. Bayer paid $300mn upfront, with total consideration of up to $2.45bn tied to milestones. The centrepiece is PER-001, an intravitreal implant for glaucoma and diabetic retinopathy — a Phase II asset with the potential to extend or eventually succeed the blockbuster Eylea franchise. That is a long-duration bet, and the market has so far largely ignored it. But it demonstrates the kind of pipeline engineering that could support the story once the legal clouds clear.

The EU’s move to allow gene-edited crops without special labelling — decided in Brussels this month — provides additional structural support to Bayer’s crop science division, where glyphosate remains a central product. The policy change could unlock new market opportunities in Europe, a region that has historically been cautious on agricultural biotechnology.

Operationally, the company is improving its financial footing without the help of a share price rally. Free cash flow reached €2.1bn in 2025, while net debt fell from €32.6bn at the end of 2024 to €29.8bn at the close of 2025. The stock has recovered about 46% from its 52-week low of €25.09, but still sits 27% below the high of €49.93. The 200-day moving average at €36.17 has been tested and held, but the 50-day line at €37.84 — only marginally above Thursday’s close — suggests the rally is not yet convincing enough to call a breakout.

With the Supreme Court ruling now days away, Bayer’s shares are likely to remain prisoners of the legal calendar. Yet beneath the binary surface, a more complex story of pipeline investment, aggressive brand defence, and gradual deleveraging is taking shape. When the ruling finally lands, the market will have to decide whether the operational substance already priced in is enough — or whether the legal overhang will take years to fully unwind.